Federated Hermes, Inc. Jounce Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$0.9 - $1.85 $330 - $678	367 Added 11.33%	3,606 $6,000
Q4 2022 Feb 13, 2023	BUY	$0.64 - $1.99 $1,874 - $5,828	2,929 Added 944.84%	3,239 $3,000
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $846 - $1,525	310 New	310 $1,000
Q4 2020 Feb 12, 2021	SELL	$6.37 - $10.33 $407 - $661	-64 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$4.58 - $10.95 $184,148 - $440,266	-40,207 Reduced 99.84%	64 $1,000
Q2 2020 Aug 13, 2020	SELL	$4.17 - $7.58 $38,714 - $70,372	-9,284 Reduced 18.73%	40,271 $278,000
Q1 2020 May 13, 2020	BUY	$2.91 - $8.7 $135,760 - $405,881	46,653 Added 1607.62%	49,555 $235,000
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $8,154 - $26,727	2,902 New	2,902 $25,000
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $1,205 - $1,784	-362 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$4.3 - $6.73 $12,117 - $18,965	-2,818 Reduced 88.62%	362 $2,000
Q1 2019 May 10, 2019	SELL	$3.43 - $6.87 $15,688 - $31,423	-4,574 Reduced 58.99%	3,180 $20,000
Q4 2018 Feb 13, 2019	BUY	$2.69 - $6.71 $15,505 - $38,676	5,764 Added 289.65%	7,754 $26,000
Q3 2018 Nov 13, 2018	BUY	$6.5 - $8.37 $11,388 - $14,664	1,752 Added 736.13%	1,990 $13,000
Q2 2018 Aug 10, 2018	BUY	$7.27 - $21.88 $1,730 - $5,207	238 New	238 $2,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.